No matter what people think of management, the BOD, the researchers, the company for that matter, it/they have stood behind "efti" and placed it in a good position on a number of fronts to give it the chance to prove itself... CR's, dilution, trial protocols and time are the shareholders enemy in biotech investing and immutep is no exception... Meanwhile "efti" is chugging along, working it's way through research centres allover the world without putting a foot wrong in various cancer indications of the highest difficulty as shown by their unmet needs status and also about to embark on a journey into the equally as difficult Auto-immune therapy world.....Only time will tell but 2024 will go a long way to reveal if "Efti" is up to task, sofar I haven't seen anything to say it isn't in there with a very good chance of proving itself and making life easier for a highly addressable market of cancer sufferers.. All my opinion...
IMM Price at posting:
34.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)